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OBJECTIVES We sought to determine whether nitroglycerin (NTG) withdrawal contributes to worsening
of endothelial dysfunction and development of the rebound phenomenon during intermittent
transdermal NTG therapy.
BACKGROUND Intermittent transdermal NTG therapy is recommended to avoid the development of
tolerance. However, this regimen may precipitate worsening angina in the NTG-free interval.
METHODS Twenty patients were randomized to intermittent transdermal NTG (0.6 mg/h; NTG group)
or no treatment (control group) five days before angiography. The risk factors for endothelial
dysfunction were similar in both groups. After diagnostic angiography, the patients
underwent quantitative angiography before and after intracoronary acetylcholine (ACh),
1024 mol/liter. Immediately after the morning study, the patch was removed from the NTG
group, and 3 h later, the ACh infusion was repeated in both groups. All patients had mild to
moderate coronary artery disease (CAD).
RESULTS The diameter of the left anterior descending coronary artery at baseline was 2.0 6 0.1 mm
in the control group and 2.6 6 0.1 mm in the NTG group (p , 0.05). Acetylcholine caused
mild vasoconstriction in the control group in the morning and afternoon (2.7 6 5.3% and
2.4 6 3.9%, respectively; p 5 NS). The NTG group demonstrated mild vasoconstriction to
ACh in the morning (3.2 6 2.8%; p 5 NS vs. control group). After patch removal, there was
a significant increase in the magnitude of vasoconstriction in the NTG group (11.6 6 3.9%,
p 5 0.04 vs. morning constriction).
CONCLUSIONS These results confirm that NTG withdrawal increases the coronary vasomotor response to
ACh in patients with mild CAD and suggests that the rebound phenomena may be secondary
to the development of endothelial dysfunction after discontinuation of NTG therapy. (J Am
Coll Cardiol 2001;37:505–9) © 2001 by the American College of Cardiology
An intermittent dosing regimen with a daily drug-free
interval is required to avoid the development of tolerance to
transdermal nitroglycerin (NTG) (1–3). A potential com-
plication of this drug-free period is the development of
rebound myocardial ischemia during the nitrate-free inter-
val (2,4,5). Indeed, withdrawal after exposure to NTG has
been associated with angina pectoris, myocardial infarction
and even sudden death (6,7).
Although the cause of nitrate tolerance remains unclear,
several different mechanisms have been proposed (8). Recent
evidence suggests that nitrate exposure is associated with
increased vascular sensitivity to vasoconstrictors, a phenome-
non which may be secondary to increased vascular production
of free radicals (9) or endothelin, or both (10). In a previous
study, we demonstrated that continuous therapy with trans-
dermal NTG was associated with the development of endo-
thelial dysfunction, as assessed by the coronary vasomotor
response to acetylcholine (ACh) (11). In this study, withdrawal
of NTG therapy for 3 h was associated with even greater
evidence of endothelial dysfunction. The cause of NTG-
induced endothelial dysfunction remains unknown; however, it
may be associated with specific changes in vascular biochem-
istry, such as increased superoxide anion production or changes
in vascular production of endothelin (9,10).
In the present study, we examined the impact of intermit-
tent transdermal NTG therapy and the early nitrate-free
interval on coronary endothelial function. We hypothesized
that 1) endothelial dysfunction would not develop during the
initial 12 h of transdermal NTG therapy; and 2) endothelial
dysfunction, as manifested by an increased sensitivity to ACh-
induced coronary vasoconstriction, would be observed during
the period after removal of transdermal NTG.
METHODS
Study group. Patients referred for diagnostic coronary
angiography were eligible to participate in this study.
Clinical exclusion criteria included previous coronary artery
bypass graft surgery or percutaneous transluminal coronary
angioplasty; unstable angina or myocardial infarction within
30 days of randomization; second- or third-degree atrioven-
tricular block; and clinically significant renal or hepatic
disease. At the time of catheterization, those with evidence
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of left main coronary artery (LMCA) atherosclerosis or
significant coronary artery disease (CAD; stenosis $60%)
involving the left anterior descending coronary artery
(LAD) or circumflex coronary artery (Cx) were excluded
from the study. Of the 48 patients enrolled in this study, 21
were excluded because of significant CAD involving the
LMCA, LAD or Cx. Five patients with angiographically
normal coronary arteries were also excluded. In two patients,
the study was interrupted because of severe bradycardia or
second-degree atrioventricular block, and in one patient, the
protocol was stopped because of technical difficulties. All
complications were treated promptly, and no patient re-
quired temporary pacing or atropine.
Study protocol. The patients were randomly assigned
to receive intermittent transdermal NTG (Ciba-Geigy,
Mississauga, Ontario), 0.6 mg/h, or no treatment (we could
not obtain placebo NTG patches), in an investigator-
blinded fashion. All patients taking long-acting nitrates
were asked to stop this medication at the time of random-
ization. Other vasodilators were discontinued 48 h before
the study. Patients were allowed to use sublingual NTG, as
required for relief of angina, but no study was carried out
within 6 h of NTG use. Starting five to seven days before
the date of the study, patients in the transdermal NTG
group were instructed to apply the transdermal NTG patch
at 10:00 PM and to remove it every morning at 10:00 AM.
On the day of the study, patients were admitted to the
catheterization laboratory at 8:00 AM for coronary angiog-
raphy. In those patients randomized to NTG, the morning
study was performed with the transdermal patch left in
place. Coronary angiography was performed using 7F diag-
nostic catheters and the Judkin’s technique. Once angio-
graphic suitability for the study had been confirmed, a single
projection best demonstrating the proximal and mid-portion
of the LAD was chosen. The study protocol included intra-
coronary infusions of 5% dextrose in water (D5W) and ACh
chloride at 1.25 ml/min for 3 min in the following sequence: 1)
control: D5W—the vehicle for ACh infusion; 2) two incre-
mental ACh infusions at concentrations of 1025 and 1024
mol/liter to achieve intracoronary concentrations of 1027 and
1026 mol/liter, respectively, assuming blood flow in the left
coronary artery of 125 ml/min; and 3) repeat control: D5W.
Coronary angiography was repeated immediately after com-
pletion of each infusion. A 3-min period was allowed to elapse
between each angiogram and the subsequent infusion to
compensate for contrast medium-induced changes in coronary
tone (12). After the completion of the morning study, the
transdermal patch was removed from patients in the NTG
group. The arterial and venous femoral sheaths were left in
place, and all patients were transferred to the recovery area.
Three hours later, the patients were returned to the catheter-
ization room, where they received an identical intracoronary
drug infusion protocol, using the same projection and radio-
graphic technique, as described earlier.
The study protocol was approved by the Committee on
Human Subjects Experimentation of the University of
Toronto, and written, informed consent was obtained from
all patients.
Quantitative measurements. Left coronary artery angio-
grams were performed by power injection (Medrad, Pitts-
burgh, Pennsylvania) of 10 to 12 ml (3 to 4 ml/s) of
nonionic contrast medium. Quantitation of coronary di-
mensions was performed using an automated edge-
detection system (CMS, Neunen, The Netherlands) and
techniques previously reported by our laboratory team (13).
A single end-diastolic frame of each angiogram was selected
by an investigator who had no knowledge of the study
groups. The longest, most clearly visualized segment of the
proximal to mid-LAD was selected. The mean lumen
diameter of the LAD segment was recorded from each
study angiogram. All films were analyzed by a technician
who had no knowledge of the patients’ treatment status.
Statistical analysis. The patients’ baseline characteristics
were compared using the unpaired t test for continuous
variables. The Fischer exact test was used to compare binary
variables. Changes in the mean lumen diameter, from
control values to each dose of ACh, were compared using
multivariate analysis of variance within a general linear
model procedure, with appropriate contrast statements
(SAS version 6.11, SAS Institute Inc., Cary, North Caro-
lina). This model allowed for analysis of intergroup changes
in the responses to ACh for both the morning and after-
noon angiograms. Furthermore, the differences between the
groups in the overall response to ACh during the morning,
versus the afternoon, could also be compared. Finally, the
procedure also allowed for univariate comparisons at base-
line and all subsequent time points between groups. A
two-sided p value ,0.05 was considered significant.
RESULTS
Patient characteristics. Ten patients were randomized to
the non-NTG arm (nine men, 59 6 4 years old) and 10
patients to NTG therapy (seven men, age 58 6 3 years old).
The groups were well matched in terms of baseline charac-
teristics and risk factors for endothelial dysfunction (Table
1). All patients had CAD, as manifested by intimal irreg-
ularities or mild to moderate obstructive disease.
Hemodynamic responses. Heart rate did not change in
either group in response to the infusion of ACh. In the
non-NTG group, there was no change in blood pressure
during the course of the study. A significant increase in
Abbreviations and Acronyms
ACh 5 acetylcholine
CAD 5 coronary artery disease
Cx 5 circumflex coronary artery
D5W 5 5% dextrose in water
LAD 5 left anterior descending coronary artery
LMCA 5 left main coronary artery
NTG 5 nitroglycerin
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systolic (from 133 6 6 to 146 6 7 mm Hg, control AM vs.
control PM; p , 0.05) and diastolic blood pressure (from
69 6 3 to 74 6 3 mm Hg, control AM vs. control PM; p ,
0.05) was observed after removal of the patch in the NTG
group.
Responses of coronary arteries. At baseline, the mean
diameter of the LAD in the non-NTG group was 2.02 6
0.09 mm, which was significantly smaller than the 2.64 6
0.10 mm observed in the NTG group (p , 0.05).
In the non-NTG group, the peak dose of ACh caused a
very small reduction in the mean LAD diameter, from
2.02 6 0.09 to 1.97 6 0.14 mm (p 5 0.11), which
represents a mean vasoconstriction of only 2.7 6 5.3%
(Fig. 1). In the afternoon, the peak dose of ACh had an
almost identical effect on the non-NTG group and caused a
change in the mean lumen diameter of the LAD from
2.02 6 0.10 to 1.98 6 0.15 mm (p 5 0.13), which also
represents a nonsignificant vasoconstriction of 2.4 6 3.9%
(Fig. 1). There was absolutely no difference between the
morning and afternoon responses to ACh (p 5 0.93). In the
NTG group, during the morning part of the study, while
the transdermal NTG patch was still in place, there was
only a very mild effect of the peak dose of ACh on the
coronary vasomotor response. The mean lumen diameter of
the LAD went from 2.64 6 0.10 to 2.56 6 0.12 mm (p 5
0.67), which represents a mean vasoconstriction of 3.2 6
2.8% (Fig. 1). During the afternoon protocol, 3 h after
removal of the NTG patch, the mean diameter of the LAD
was reduced to 2.17 6 0.08 at baseline (p , 0.05 vs.
morning control, NTG group). The intracoronary infusion
of ACh caused a further reduction in the LAD diameter to
1.93 6 0.12 mm (p , 0.05 vs. afternoon control, NTG
group), which represents a vasoconstriction of 11.6 6 3.9%
(p 5 0.04 vs. morning constriction, NTG group) (Fig. 1).
Multivariate analysis of variance revealed that there was a
highly significant difference between the responses of the
NTG group and those of the non-NTG treatment group
(p , 0.001). The reduction in the LAD diameter after
patch removal, as well as the significant vasoconstrictive
response to ACh observed in the afternoon, are illustrated in
Figure 2.
DISCUSSION
The development of tolerance to continuous transdermal
NTG therapy occurs rapidly after the initiation of therapy
and carries important clinical implications. The only effec-
tive method of preventing tolerance to NTG has been the
use of dosing schedules that provide low or absent plasma
NTG levels for a portion of the day. A number of studies
have determined that intermittent therapy with transdermal
NTG is effective in the prevention of tolerance, and this
regimen is approved and indicated for the treatment of
angina. However, there are potential problems associated
with intermittent NTG therapy. A patient receiving mono-
therapy with nitrates will have no coverage during the
nitrate-free period and may require combined therapy with
a beta-blocker or calcium channel blocker. In addition, there
is also concern that anginal symptoms may be exacerbated
during the nitrate-free period, because of a phenomenon
known as “rebound ischemia” (6). Although the cause of
rebound ischemia is uncertain, there is evidence to suggest
that this is a clinically relevant problem.
Rebound ischemia. For nearly 50 years, several studies
have reported what was termed the “withdrawal hazards” of
Table 1. Demographic, Clinical and Laboratory Characteristics of the Study Groups
Characteristic
Non-NTG Group
(n 5 10)
NTG Group
(n 5 10) p Value
Age (years) 59 6 4 58 6 3 NS
Gender (M/F) 9/1 7/3 NS
Hypertension (n) 4 2 NS
Family history of CAD (n) 6 5 NS
Cigarette smoking (n) 2 2 NS
HDL cholesterol (mmol/liter) 1.1 6 0.1 1.4 6 0.1 NS
LDL cholesterol (mmol/liter) 2.5 6 0.3 2.7 6 0.3 NS
Triglycerides (mmol/liter) 1.3 6 0.2 1.5 6 0.3 NS
Total no. of risk factors* 3.1 6 0.4 3.0 6 0.5 NS
*Risk factors include age .45 years, male gender, hypertension, non–insulin-dependent diabetes, family history of CAD, total
cholesterol .5.3 mmol/liter and current smoker. Data are presented as the mean value 6 SEM or number of subjects.
CAD 5 coronary artery disease; F 5 female; HDL 5 high density lipoprotein; LDL 5 low density lipoprotein; M 5 male;
NS 5 not significant; NTG 5 nitroglycerin.
Figure 1. Percent vasoconstriction of the LAD in response to ACh in the
morning (AM, open bars) and afternoon (PM, solid bars) in the
non-NTG and NTG groups. There was a significant increase in the degree
of vasoconstriction in the NTG group after removal of the transdermal
NTG patch and also a significant difference in the vasomotor response
between the two groups. *p 5 0.04 vs. NTG morning response. Data are
expressed as the mean value 6 SEM.
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NTG. In most cases, this was manifested as worsening
angina, myocardial infarction or sudden death among work-
ers of the explosives industry after they had left the plant for
two or three days (6,7). Given the nature of NTG exposure
in these reports, it is difficult to extrapolate these observa-
tions to the clinical use of this compound. In more recent
investigations of intermittent NTG therapy, an increase in
angina and myocardial ischemia during the nitrate-free
interval was seen (2,4,14). In one multicenter, randomized
controlled trial evaluating the efficacy of intermittent trans-
dermal NTG in patients with stable angina, 9 of 138
patients receiving active treatment fulfilled the defined
criteria for a significant increase in rest angina after patch
removal. None of the 68 patients in the control group
developed rest angina during the patch-off interval (2). In
another placebo-controlled, crossover design study compar-
ing the effects of continuous versus intermittent NTG
therapy in patients with stable angina, a higher incidence of
anginal attacks was seen during the NTG-free interval (4).
Similar clinical results were documented more recently by
Pepine et al. (14). Although these reports are a cause of
concern, no such effects were reported in other studies
(15–17), including a large-scale trial of intermittent trans-
dermal NTG therapy (3).
Zero-hour effect. Intermittent transdermal NTG therapy
has also been shown to have adverse effects on exercise
performance during the nitrate-free interval. In patients
with stable angina, intermittent transdermal NTG is asso-
ciated with a decrease in the angina threshold for 4 to 6 h
after discontinuation of therapy (5). In a similar study by
Pepine et al., an increase in the frequency of angina during
the patch-off interval was documented by patients, and this
subjective finding was supported by a corresponding trend
toward an increase in ambulatory electrocardiographic evi-
dence of ischemia in this same period (14). DeMots and
Glasser (2) demonstrated that 12 h after the removal of the
transdermal NTG or placebo patch, the placebo group was
able to exercise longer than the group receiving active
therapy—a phenomenon that was called the “zero hour
effect.” Similar results were reported in another large trial of
intermittent NTG therapy (3).
Nitroglycerin and endothelial dysfunction. In a recent
study by our group, we documented an abnormal coronary
vasomotor response to the endothelium-dependent vasodi-
lator ACh in patients undergoing continuous therapy with
transdermal NTG (11). The abnormal vasoconstriction
observed was accentuated after discontinuation of therapy.
We hypothesized that these results were secondary to the
development of endothelial dysfunction caused by biochem-
ical changes in the coronary vasculature that occurred during
NTG therapy. In the current study, we used a similar
protocol to test the coronary vasomotor responses to ACh
during intermittent therapy with transdermal NTG and
after patch removal. This study documents that intermittent
NTG therapy is not associated with worsening of endothe-
lial dysfunction during the period of transdermal NTG
exposure. Withdrawal of NTG, however, was associated
with aggravating endothelial dysfunction. Patients receiving
intermittent transdermal NTG demonstrated a significant
increase in the magnitude of vasoconstriction 3 h after patch
removal, an effect that was not seen in the control group.
This interval of 3 h was chosen on the basis of the results of
studies that documented a decline in NTG plasma concen-
trations to undetectable levels within 1 h of patch removal
(18,19). This increase in the severity of vasoconstriction
after NTG withdrawal was five times larger in the active
therapy arm than in the control group (Fig. 1). There was
no evidence of tolerance in the NTG arm, given the fact
that in this group, the mean LAD diameter at baseline was
significantly larger than that in the control group. The
Figure 2. Coronary angiograms from patients in the non-NTG group (panel A) and NTG group (panel B). The angiograms were obtained at the time
of the morning control solution of D5W (Control AM), during 10
24 mol/liter of ACh in the morning (ACh24 AM), during the afternoon control solution
of D5W (Control PM) and during 10
24 mol/liter of ACh in the afternoon (ACh24 PM). The white arrow identifies the LAD.
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mechanism underlying this response is not clear. We hy-
pothesize that during NTG therapy, biochemical changes
develop that make the coronary vasculature more sensitive
to vasoconstrictors (9,10,20). During the period of NTG
exposure, these biochemical changes develop, but are bal-
anced by the dilating effect of the nitrate. After withdrawal
of NTG therapy, these biochemical changes persist, but are
no longer opposed by the vasodilating properties of the
nitrate. The resulting imbalance between dilator and con-
strictor systems is manifested as a greater sensitivity to the
vasoconstrictor actions of ACh.
Study limitations. It is important to consider some limi-
tations of this study. Differences in baseline characteristics
can potentially influence our results. A crossover design
would not be possible given the need for repeat coronary
angiography. We carefully monitored all risk factors for
endothelial dysfunction, because endothelium-dependent
responses to ACh have been related to risk factors (21).
There were no significant differences between the two
groups for any of the baseline characteristics commonly
reported in previous studies that evaluated the coronary
vasomotor response to ACh (11,22).
Clinical relevance. We believe these findings have clinical
significance. Although the incidence of clinically significant
episodes of ischemia after transdermal NTG therapy is
relatively low (it was seen in only 6.5% of the patients in the
report by DeMots and Glasser [2]), physicians should be
aware of this possibility in patients on transdermal therapy.
In a recent, large, retrospective study, the use of long-term
nitrate therapy appeared to be harmful in a group of patients
with CAD. These analyses raise concern about the potential
adverse effects of long-acting nitrate therapy in chronic
CAD (23). Furthermore, the possibility of rebound isch-
emia suggests that intermittent transdermal therapy should
be used with caution in patients with variable threshold
angina or recent unstable ischemic episodes.
Acknowledgments
The authors thank the staff of the Bayer Cardiovascular
Clinical Research Laboratory of the Mount Sinai Hospital:
May Chan, RN, Rebecca Allan, RN, Wilson Chan and
Thom Benson, RN, for their help in the completion of these
studies.
Reprint requests and correspondence: Dr. John D. Parker,
Mount Sinai Hospital, 600 University Avenue, Suite 1609, To-
ronto, Ontario M5G-1X5. E-mail: jdp@inforamp.net.
REFERENCES
1. Parker JO, Farrell B, Lahey KA, Moe G. Effect of intervals between
doses on the development of tolerance to isosorbide dinitrate. N Engl
J Med 1987;316:1440–4.
2. DeMots H, Glasser SP. Intermittent transdermal nitroglycerin ther-
apy in the treatment of chronic stable angina. J Am Coll Cardiol
1989;13:786–95.
3. Parker JO, Amies MH, Hawkinson RW, et al., the Minitran Efficacy
Study Group. Intermittent transdermal nitroglycerin therapy in angina
pectoris: clinically effective without tolerance or rebound. Circulation
1995;91:1368–74.
4. Ferratini M, Pirelli S, Merlini P, Silva P, Pollavini G. Intermittent
transdermal nitroglycerin monotherapy in stable exercise- induced
angina: a comparison with a continuous schedule. Eur Heart J
1989;10:998–1002.
5. Parker JD, Parker AB, Farrell B, Parker JO. Intermittent transdermal
nitroglycerin therapy: decreased anginal threshold during the nitrate-
free interval. Circulation 1995;91:973–8.
6. Lange RL, Reid MS, Tresch DD, Keelan MH, Bernhard VM,
Coolidge G. Nonatheromatous ischemic heart disease following with-
drawal from chronic industrial nitroglycerin exposure. Circulation
1972;46:666–78.
7. Morton WE. Occupational habituation to aliphatic nitrates and the
withdrawal hazards of coronary disease and hypertension. J Occup
Med 1977;19:197–200.
8. Parker JD, Parker JO. Nitrate therapy for stable angina pectoris.
N Engl J Med 1998;338:520–31.
9. Munzel T, Sayegh H, Freeman BA, Tarpey MM, Harrison DG.
Evidence for enhanced vascular superoxide anion production in nitrate
tolerance: a novel mechanism underlying tolerance and cross-tolerance.
J Clin Invest 1995;95:187–94.
10. Munzel T, Giaid A, Kurz S, Stewart DJ, Harrison DG. Evidence for
a role of endothelin 1 and protein kinase C in nitroglycerin tolerance.
Proc Natl Acad Sci USA 1995;92:5244–8.
11. Caramori PR, Adelman AG, Azevedo ER, Newton GE, Parker AB,
Parker JD. Therapy with nitroglycerin increases coronary vasoconstric-
tion in response to acetylcholine. J Am Coll Cardiol 1998;32:1969–74.
12. Jost S, Rafflenbeul W, Gerhardt U, et al. Influence of ionic and
non-ionic radiographic contrast media on the vasomotor tone of
epicardial coronary arteries. Eur Heart J 1989;10 Suppl F:60–5.
13. Adelman AG, Cohen EA, Kimball BP, et al. A comparison of
directional atherectomy with balloon angioplasty for lesions of the left
anterior descending coronary artery. N Engl J Med 1993;329:228–33.
14. Pepine CJ, Lopez LM, Bell DM, Handberg TE, Marks RG, McGor-
ray S. Effects of intermittent transdermal nitroglycerin on occurrence
of ischemia after patch removal: results of the second Transdermal
Intermittent Dosing Evaluation Study (TIDES- II). J Am Coll
Cardiol 1997;30:955–61.
15. Cowan JC, Bourke JP, Reid DS, Julian DG. Prevention of tolerance to
nitroglycerin patches by overnight removal. Am J Cardiol 1987;60:
271–5.
16. Schaer DH, Buff LA, Katz RJ. Sustained antianginal efficacy of
transdermal nitroglycerin patches using an overnight 10-hour nitrate-
free interval. Am J Cardiol 1988;61:46–50.
17. Holdright DR, Katz RJ, Wright CA, et al. Lack of rebound during
intermittent transdermal treatment with glyceryl trinitrate in patients
with stable angina on background beta-blocker. Br Heart J 1993;69:
223–7.
18. Todd PA, Goa KL, Langtry HD. Transdermal nitroglycerin (glyceryl
trinitrate): a review of its pharmacology and therapeutic use. Drugs
1990;40:880–902.
19. Curry SH, Kwon HR, Perrin JH, Culp JR, Pepine CJ, Yu W.
Nitroglycerin levels after administration via transdermal therapeutic
system or nitroglycerin ointment (letter). Lancet 1984;1:1297.
20. Bauer JA, Fung HL. Effect of apparent elimination half-life on
nitroglycerin-induced hemodynamic rebound in experimental heart
failure. Pharmacol Res 1993;10:1341–5.
21. Vita JA, Treasure CB, Nabel EG, et al. Coronary vasomotor response
to acetylcholine relates to risk factors for coronary artery disease (see
comments). Circulation 1990;81:491–7.
22. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P.
The effect of cholesterol-lowering and antioxidant therapy on
endothelium-dependent coronary vasomotion (see comments). N Engl
J Med 1995;332:488–93.
23. Nakamura Y, Moss AJ, Brown MW, Kinoshita M, Kawai C, the
Multicenter Myocardial Ischemia Research Group. Long-term nitrate
use may be deleterious in ischemic heart disease: a study using the
databases from two large-scale postinfarction studies (see comments).
Am Heart J 1999;138:577–85.
509JACC Vol. 37, No. 2, 2001 Azevedo et al.
February 2001:505–9 Endothelial Dysfunction and Rebound Phenomenon
